Received Jun 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HIBV | HIB (HIBERIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 9532H | — |
administered a dose of Hiberix subcutaneously instead of intramuscularly; This non-serious case was reported by a nurse via call center representative and described the occurrence of intramuscular formulation administered by other route in a 2-year-old female patient who received Hib (Hiberix) (batch number 9532H, expiry date 16-JUL-2026) for prophylaxis. On 06-JUN-2025, the patient received Hiberix. On 06-JUN-2025, an unknown time after receiving Hiberix, the patient experienced intramuscular formulation administered by other route (Verbatim: administered a dose of Hiberix subcutaneously instead of intramuscularly). The outcome of the intramuscular formulation administered by other route was not applicable. Additional Information: GSK Receipt Date: 06-JUN-2025 Nurse called to request information about the possible routes of administration if another nurse administered a dose of Hiberix subcutaneously instead of intramuscularly, which led intramuscular formulation administered by other route.